Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
Category: #health  By Mateen Dalal  Date: 2019-05-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn

The acquisition would help Merck strengthen its presence in the renal cell carcinoma space and support its cancer drug portfolio.

U.S. pharmaceutical conglomerate, Merck & Co. Inc. has recently agreed to purchase Dallas based Peloton Therapeutics Inc. for an estimated $1.05 billion in cash, acquiring access to the firm’s lead kidney cancer treatment portfolio.

For the record, Peloton is a clinical-stage biotech firm focused on cancer treatments. The company’s business hinges on two drugs that are designed to block a transcription factor dubbed hypoxia-inducible factor-2 alphaα (HIF-2α) which, among other things, regulates the way a body responds to low oxygen levels. 

According to sources, Peloton’s acquisition could strengthen Merck’s presence in the renal cell carcinoma field and support its cancer drug portfolio. Besides, Merck’s famous immunotherapy Keytruda was also been approved recently in the U.S. for treating renal cell cancer.

Speaking on the move, Dr. Roger M. Perlmutter, Merck Research Laboratories President, said that the acquisition validates the company’s strategy in pursuing new therapeutic candidates based on highly promising and innovative research.

He said that that scientists at Peloton have applied their know-how in HIF-2α biology to develop PT2977, which has shown commendable activity in the treatment of renal cell carcinoma. Perlmutter added that Merck is furthering this late-stage asset as part of its oncology R&D program.

Reportedly, from an older mid-stage trial, which included patients whose cancer had spread despite being treated with at least one therapy, around 24% of them subjected to Peloton’s treatment showed at least 30% shrinkage of targeted lesions.

Positive about its pipeline, Peloton was earlier seeking to go public and had also allotted a pricing range of $15 to $17 per share for its initial public offering recently. Nevertheless, with Merck’s recent deal, Peloton shareholders could be eligible to acquire a further $1.15 billion on attaining certain regulatory and sales milestones.

The deal is expected to close in the third quarter of 2019. Meanwhile, shares of Merck were reported to have gained 34.7% in the last 12 months, while the S&P 500 gained 3.9%.

Source Credit: https://www.reuters.com/article/us-merck-co-deals/merck-buys-peloton-to-expand-its-kidney-cancer-treatment-portfolio-idUSKCN1SR136

https://www.marketwatch.com/story/merck-to-acquire-peloton-therapeutics-for-upfront-payment-of-105-billion-in-cash-2019-05-21

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Cryptocurrency platform Binance acquires dApp startup DappReview
Cryptocurrency platform Binance acquires dApp startup DappReview
By Mateen Dalal

Binance, a renowned cryptocurrency exchange platform where more than 100 cryptocurrencies are traded, reportedly announced the acquisition of DappReview, an evaluation platform offering advertising and data-driven research services to blockchain-base...

Amneal gains FDA nod for launch of Revatio® & Amicar® tablets
Amneal gains FDA nod for launch of Revatio® & Amicar® tablets
By Mateen Dalal

Amneal Pharmaceuticals, Inc. has made some consistent ripples in the generics and specialty pharmaceutical industry. Recently, the company made headlines when it revealed attaining final approval from the U.S. FDA on its ANDA (Abbreviated New Drug Ap...

Prescient expands PTX-200 trial after it eradicates cancer completely
Prescient expands PTX-200 trial after it eradicates cancer completely
By Mateen Dalal

Prescient Therapeutics, a renowned small molecule drug development firm aimed at developing new cancer therapies, reportedly announced that it is extending its Phase 1b trial in patients with AML (acute myeloid leukemia) after the disease was complet...